Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab and Anlotinib with Radiotherapy in Recurrent/Metastatic ESCC
NCT06681285Phase 2Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The Fourth Hospital of Hebei Medical University. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06681285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06681285.